{"id":28774,"date":"2017-10-14T05:43:06","date_gmt":"2017-10-14T03:43:06","guid":{"rendered":"https:\/\/www.abcsg.org\/?page_id=28774"},"modified":"2021-05-05T15:54:14","modified_gmt":"2021-05-05T13:54:14","slug":"abcsg-publications-peer-reviewed-2011-2015","status":"publish","type":"page","link":"https:\/\/www.abcsg.org\/en\/veroeffentlichungen\/publications\/abcsg-publications-peer-reviewed-2011-2015\/","title":{"rendered":"ABCSG-Publications (peer reviewed) 2011-2015"},"content":{"rendered":"
\n
<\/span>2015<\/div>
\n

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype<\/h4>\n

Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J<\/p>\n

Annals of Oncology 00:1-7, 2015. Epub 2015 May 1.<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25935792<\/a><\/p>\n

\n

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial<\/h4>\n

Gnant M, Pfeiler G, Dubsky P, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger G, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer C<\/p>\n

The Lancet<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26040499<\/a><\/p>\n

\n

Final 10-year results of the Breast International Group 2\u201398 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer<\/h4>\n

Sonnenblick A, Francis P A, Azim Jr. H A, de Azambuja E, Nordenskj\u00f6ld B, Guti\u00e9rez J, Quinaux E, Mastropasqua M G, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown JFrancis P A, Azim Jr. H A, de Azambuja E, Nordenskj\u00f6ld B, Guti\u00e9rez J, Quinaux E, Mastropasqua M G, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J<\/p>\n

European Journal of Cancer<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26074397<\/a><\/p>\n

\n

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials<\/h4>\n

EBCTCG, Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R<\/p>\n

The Lancet, 2015 Oct 3;386(10001):1353\u20131361. Epub 2015 Jul 23.<\/p>\n

https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(15)60908-4\/fulltext<\/a><\/p>\n

\n

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials<\/h4>\n

EBCTCG, Dowsett M, Forbes F, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Th\u00fcrlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R<\/p>\n

The Lancet. 2015 Oct 3;386(10001):1341-52. Epub 2015 Jul 23.<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26211827<\/a><\/p>\n

\n

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients<\/h4>\n

Kandioler D, Mittlb\u00f6ck M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, Hofbauer F, Samonigg H, Gnant M, Teleky B, K\u00fchrer I<\/p>\n

EBioMedicine. 2015 Jun 8;2(8):823-8. eCollection 2015 Aug.<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4563117\/<\/a><\/p>\n

\n

Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients<\/h4>\n

Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M.<\/p>\n

PharmacoEconomics (2015) 33:179\u2013190 DOI 10.1007\/s40273-014-0227-x<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25404424<\/a><\/p>\n

\n

Tailoring therapies – improving the management of early breast cancer: St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.<\/h4>\n

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ; Panel Members<\/p>\n

Annals of Oncology 2015 Aug;26(8):1533-46. Epub 2015 May 4.<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25939896<\/a><\/p>\n

\n

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial<\/h4>\n

Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R and Gnant MFilipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R and Gnant M<\/p>\n

British Journal of Cancer (2015) 112, 1405\u20131410 | doi: 10.1038\/bjc.2015.98<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25867274<\/a><\/p>\n

\n

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials<\/h4>\n

EBCTCG, Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Th\u00fcrlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R.<\/p>\n

The Lancet, 2015 Oct 3;386(10001):1341-1352. Epub 2015 Jul 23.<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26211827<\/a><\/p>\n

\n

Adjuvant Bisphosphonates in Breast Cancer Treatment<\/h4>\n

Knauer M, Th\u00fcrlimann B.<\/p>\n

Breast Care 2014;9:319\u2013322 DOI: 10.1159\/000368760<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4322690\/<\/a><\/p>\n

\n

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay<\/h4>\n

Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS.<\/p>\n

Bio Med Central DOI 10.1186\/s12920-015-0129-6<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26297356<\/a><\/p>\n

\n

St. Gallen\/Vienna 2015: A Brief Summary of the Consensus Discussion<\/h4>\n

Gnant M, Thomssen C, Harbeck N.<\/p>\n

Breast Care 2015;10:124\u2013130 DOI: 10.1159\/000430488<\/p>\n

https:\/\/www.karger.com\/Article\/Fulltext\/430488<\/a><\/p>\n

\n

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial<\/h4>\n

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman R E, Jones L, Ellis I, Cuzick J<\/p>\n

The Lancet doi 10.1016\/S0140-6736(15)01129-0<\/p>\n

https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(15)01129-0\/fulltext<\/a><\/p>\n

\n<\/div><\/div>\n
<\/span>2014<\/div>
\n

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer<\/h4>\n

Filipits M, Nielsen T, Rudas M, Greil R, St\u00f6ger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, M\u00fcller-Holzner E, Singer C, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens J, Gnant M, for the Austrian Breast and Colorectal Cancer Study Group<\/p>\n

Clinical Cancer Research<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24520097<\/a><\/p>\n

\n

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial<\/h4>\n

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, van Laethem J, Thaler J, Bridgewater J, Norgard Peterson L, Blons H, Collette L, van Cutsen E, Rougier P, Salazar R, Bedenne L, Emile J, Laurent-Puig P, Lepage C<\/p>\n

The Lancet Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24928083<\/a><\/p>\n

\n

Preoperative Treatment with Capecitabine, Cetuximab and Radiotherapy for Primary Locally Advenced Rectal Cancer – A Phase II Clinical Trial<\/h4>\n

Eisterer W, De Vries A, \u00d6fner D, Rabl H, Koplm\u00fcller R, Greil R, Tschmelitsch J, Schmid R, Kapp K, Lukas P, Sedlmayer F, H\u00f6fler G, Gnant M, Thaler J<\/p>\n

Anticancer Research – International Journal of Cancer Research and Treatment<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25368289<\/a><\/p>\n

\n

Role of bisphosphonates in postmenopausal women with breast cancer<\/h4>\n

Gnant M<\/p>\n

Cancer Treatment Reviews<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23906846<\/a><\/p>\n

\n

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12<\/h4>\n

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R<\/p>\n

Annals of Oncology 2015 Feb;26(2):313-20. Epub 2014 Nov 17.<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25403582<\/a><\/p>\n

\n

Prediction of Late Distant Recurrence After 5 Years of Endocriner Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score<\/h4>\n

Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M<\/p>\n

Journal of Clinical Oncology 2015 March 10;33(8):916-922. Epub 2014 Oct 20.<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25332252<\/a><\/p>\n<\/div><\/div>\n

<\/span>2013<\/div>
\n

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8<\/h4>\n

Goetz MP, Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN<\/p>\n

Clinical Cancer Research<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23213055<\/a><\/p>\n

\n

Efficacy of tamoxifen \u00b1 aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial<\/h4>\n

Pfeiler G, St\u00f6ger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger G, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M<\/p>\n

British Journal of Cancer<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23511562<\/a><\/p>\n

\n

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer<\/h4>\n

Pfeiler G, K\u00f6nigsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M, Dubsky P<\/p>\n

British Journal of Cancer<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3777005\/<\/a><\/p>\n

\n

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial<\/h4>\n

Gnant M, Pfeiler G, St\u00f6ger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger G, Samonigg H, Fesl C, Jakesz R on behalf of the Austrian Breast and Colorectal Cancer Study Group<\/p>\n

British Journal of Cancer<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23868011<\/a><\/p>\n

\n

Preparing for Prospective Clinical Trials: A National Initiative of an Excellence Registry for Consecutive Pancreatic Cancer Resections<\/h4>\n

Gangl O, Sahora K, Kornprat P, Margreiter C, Primavesi F, Bareck E, Schindl M, L\u00e4ngle F, \u00d6fner D, Mischinger H-J, Pratschke J, Gnant M, F\u00fcgger R<\/p>\n

World Journal of Surgery<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24121365<\/a><\/p>\n

\n

The EndoPredict score provides prognostic information on late distant metastases in ER\u00fe\/HER2 breast cancer patients<\/h4>\n

Dubsky P, Brase J C, Jakesz R, Rudas M, Singer C F, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann M C, Petry C, Weber K E, Fisch K, Kronenwett R, Gnant M, Filipits M on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)<\/p>\n

British Journal of Cancer<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24157828<\/a><\/p>\n

\n

Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1<\/h4>\n

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Wei\u00dfenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, B\u00f6hm G, H\u00f6fler G, Samonigg H, Schaberl-Moser R, Balic M and Dandachi N<\/p>\n

Modern Pathology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24309322<\/a><\/p>\n

\n

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)<\/h4>\n

Steger G, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann B, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer A, Singer C, Muss C, Jakesz R, Gampenrieder S, Zielinski C, Fesl C, Gnant M on behalf of the Austrian Breast and Colorectal Study Group (ABCSG)<\/p>\n

Annals of Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24347519<\/a><\/p>\n

\n

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone<\/h4>\n

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlinertisch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens J, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T, on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)<\/p>\n

Annals of Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24347518<\/a><\/p>\n<\/div><\/div>\n

<\/span>2012<\/div>
\n

Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer<\/h4>\n

Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F, Gnant M, Zielinski C, Steger G<\/p>\n

European Journal of Cancer<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22459763<\/a><\/p>\n

\n

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer<\/h4>\n

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer C F, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann M C, Petry C, Weber K E, Kronenwett R, Brase J C, Gnant M<\/p>\n

Annals of Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3574544\/<\/a><\/p>\n

\n

Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group<\/h4>\n

Dubsky P, Jakesz R, Mlineritsch B, P\u00f6stlberger S, Samonigg H, Kwasny W, Tausch C, St\u00f6ger H, Haider K, Fitzal F, Singer C, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger G, Greil R, Filipcic L, Gnant M<\/p>\n

Journal of Clinical Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22271481<\/a><\/p>\n

\n

Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type Breast Cancer Patients<\/h4>\n

Fitzal F, Mittlboeck M, Steger G, Bartsch R, Rudas M, Dubsky F, Riedl O, Jakesz R, Gnant M<\/p>\n

Annals of Surgical Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21743980<\/a><\/p>\n

\n

The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis<\/h4>\n

Hadji P, Coleman R, Gnant M, Green J<\/p>\n

Annals of Oncology Advance Access<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22730099 <\/a><\/p>\n

\n

Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer<\/h4>\n

Knauer M, Gnant M, Fitzal F<\/p>\n

Breast Care<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22553475<\/a><\/p>\n

\n

Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – a two stage phase II clinical trial<\/h4>\n

Resch G, de Vries A, \u00d6fner D, Eisterer W, Rabl H, Jagoditsch M, Gnant M, Thaler J<\/p>\n

Radiotherapy and Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21741716<\/a><\/p>\n

\n

Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer<\/h4>\n

Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsky P, Jesch B, Heinzl H, Birner P<\/p>\n

Breast Cancer Research and Treatment<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22350732<\/a><\/p>\n

\n

Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)<\/h4>\n

Tausch C, Taucher S, Dubsky P, Seifer M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M<\/p>\n

Annals of Surgical Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22207051<\/a><\/p>\n

\n

Response to: Dual inhibition of HER2 in breast cancer treatment<\/h4>\n

Gnant M, Steger G<\/p>\n

The Lancet<\/p>\n

https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(12)60068-3\/fulltext<\/a><\/p>\n

\n

Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature<\/h4>\n

Gnant M, Philippe Cl\u00e9zardin<\/p>\n

Cancer Treatment Reviews<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21983264<\/a><\/p>\n

\n<\/div><\/div>\n
<\/span>2011<\/div>
\n

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer<\/h4>\n

Bago-Horvath Z, Rudas M, Dubsky P<\/p>\n

American Association for Cancer Research<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21998336<\/a><\/p>\n

\n

A new Molecular Predictor of Distant Recurrence in ER-positive, HER2-negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors<\/h4>\n

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer Ch, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer Ch, M\u00fcller V, J\u00e4nicke F, Schmidt M, K\u00f6lbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber K, Feder I, Hennig G, Kronenwett R, Gehrmann M, Gnant M<\/p>\n

American Association for Cancer Research<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21807638<\/a><\/p>\n

\n

62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer<\/h4>\n

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Poestlberger S, Steger G, Jakesz R, Singer C, Eidtmann H, Greil R<\/p>\n

Bone<\/p>\n

https:\/\/www.researchgate.net\/publication\/<\/a><\/p>\n

\n

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial<\/h4>\n

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel Ch, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl Ch, Greil R<\/p>\n

The Lancet Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21641868<\/a><\/p>\n

\n

Zoledronic acid in breast cancer: latest findings and interpretations<\/h4>\n

Gnant M<\/p>\n

Therapeutic Advances in Medical Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3210470\/<\/a><\/p>\n

\n

Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT3NxM0, low rectal cancer a phase II study<\/h4>\n

\u00d6fner D, DeVries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, J\u00e4ger R, Offner F, Gnant M, Thaler J<\/p>\n

Strahlentherapie und Onkologie<\/p>\n

https:\/\/www.researchgate.net\/publication\/<\/a><\/p>\n

\n

Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients with Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial<\/h4>\n

Pfeiler G, K\u00f6nigsberg R, Fesl Ch, Mlineritsch B, Stoeger H, Singer CF, P\u00f6stlberger S, Steger G, Seifert m, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth Ch, Gnant M<\/p>\n

Journal of Clinical Oncology<\/p>\n

https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2010.33.2585<\/a><\/p>\n

\n

Zoledronic acid for adjuvant use in patients with breast cancer<\/h4>\n

Ressler S, Mlineritsch B, Greil R<\/p>\n

Expert review of anticancer therapy<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21417849<\/a><\/p>\n

\n

Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14<\/h4>\n

Tausch C, Steger G, Haid A, Jakesz R, Fridrik M, Reitsamer R, P\u00f6stlberger S, Lang A, Gnant M, Greil R<\/p>\n

The Breast Journal<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21450019<\/a><\/p>\n

\n

Adjuvant bisphosphonates – an option with low estrogen?<\/h4>\n

Gnant M<\/p>\n

Nature Reviews<\/p>\n

https:\/\/www.nature.com\/articles\/nrclinonc.2011.170<\/a><\/p>\n<\/div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":28699,"menu_order":321,"comment_status":"closed","ping_status":"closed","template":"page-publikationen.php","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-28774","page","type-page","status-publish","hentry"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-08 01:14:59","action":"delete","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/28774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/comments?post=28774"}],"version-history":[{"count":2,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/28774\/revisions"}],"predecessor-version":[{"id":29289,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/28774\/revisions\/29289"}],"up":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/28699"}],"wp:attachment":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media?parent=28774"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/tags?post=28774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}